Background: Crohn's disease (CD) patients are typically underweight; however, a growing cohort of overweight CD patients is emerging. The current study investigates whether body mass index (BMI) or volumetric fat parameters can be used to predict morbidity after ileocolectomy for CD. Methods: One hundred and forty-three CD patients who underwent elective ileocolectomy were identified from our Inflammatory Bowel Disease (IBD) Registry. Patient demographics and operative outcomes were recorded. Visceral (VA) and subcutaneous (SA) adiposity and abdominal circumference (AC) were analyzed on preoperative CT scans using Aquarius iNtuition software. A visceral/subcutaneous ratio (VSR) was calculated. Results: BMI correlated with SA (p = 0.0001), VA (p = 0.0001) and AC (p = 0.0001) but not VSR (p > 0.05). BMI, VA and AC did not predict surgical morbidity (p > 0.05). In multivariate regression analysis, family history of IBD (p = 0.009), high American Society of Anesthesiologists score (p = 0.02) and increased VSR (p = 0.03) were independent predictors of postoperative morbidity. Conclusions: The visceral/subcutaneous fat ratio is a more reliable predictor of postoperative outcomes in CD patients undergoing ileocolectomy than conventional adiposity markers such as BMI. Preoperative calculation of the visceral/subcutaneous fat ratio offers the opportunity to optimize high-risk surgical patients, thus improving outcomes.

Keywords:
Fat ratio, Crohn’s disease, Complications, Surgery, Adipose tissue
1.
Flegal KM, Carroll MD, Kit BK, Ogden CL: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497.
2.
Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-1675.
3.
Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, Silman AJ: Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997;40:1955-1961.
4.
Bertin B, Desreumaux P, Dubuquoy L: Obesity, visceral fat and Crohn's disease. Curr Opin Clin Nutr Metab Care 2010;13:574-580.
5.
Tsujinaka S, Konishi F, Kawamura YJ, Saito M, Tajima N, Tanaka O, Lefor AT: Visceral obesity predicts surgical outcomes after laparoscopic colectomy for sigmoid colon cancer. Dis Colon Rectum 2008;51:1757-1765; discussion 1765-1767.
6.
Park CM, Park JS, Cho ES, Kim JK, Yu JS, Yoon DS: The effect of visceral fat mass on pancreatic fistula after pancreaticoduodenectomy. J Invest Surg 2012;25:169-173.
7.
Hagiwara M, Miyajima A, Hasegawa M, Jinzaki M, Kikuchi E, Nakagawa K, Oya M: Visceral obesity is a strong predictor of perioperative outcome in patients undergoing laparoscopic radical nephrectomy. BJU Int 2012;110:E980-E984.
8.
Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR: The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:482-488.
9.
Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur M, Cortot A, Capron M, Auwerx J, Colombel JF: Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73-81.
10.
Causey MW, Johnson EK, Miller S, Martin M, Maykel J, Steele SR: The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment. Dis Colon Rectum 2011;54:1488-1495.
11.
Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J: Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002;21:51-57.
12.
Sheehan AL, Warren BF, Gear MW, Shepherd NA: Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79:955-958.
13.
Zulian A, Cancello R, Micheletto G, Gentilini D, Gilardini L, Danelli P, Invitti C: Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 2012;61:86-94.
14.
Erhayiem B, Dhingsa R, Hawkey CJ, Subramanian V: Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease. Clin Gastroenterol Hepatol 2011;9:684-687 e1.
15.
Yajima Y, Narui T, Ishii M, Abe R, Ohtsuki M, Goto Y, Endo S, Yamada K, Ito M: Computed tomography in the diagnosis of fatty liver: total lipid content and computed tomography number. Tohoku J Exp Med 1982;136:337-342.
16.
Sugisawa N, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M: Intra-abdominal infectious complications following gastrectomy in patients with excessive visceral fat. Gastric Cancer 2012;15:206-212.
17.
Healy LA, Ryan AM, Sutton E, Younger K, Mehigan B, Stephens R, Reynolds JV: Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis 2010;25:1293-1299.
18.
Rickles AS, Iannuzzi JC, Mironov O, Deeb AP, Sharma A, Fleming FJ, Monson JR: Visceral obesity and colorectal cancer: are we missing the boat with BMI? J Gastrointest Surg 2013;17:133-143; discussion 143.
19.
Ballian N, Lubner MG, Munoz A, Harms BA, Heise CP, Foley EF, Kennedy GD: Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma. J Surg Oncol 2012;105:365-370.
20.
Cecchini S, Cavazzini E, Marchesi F, Sarli L, Roncoroni L: Computed tomography volumetric fat parameters versus body mass index for predicting short-term outcomes of colon surgery. World J Surg 2011;35:415-423.
21.
Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C: Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012;18:1550-1557.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.